Submit a comment

Thymosin-induced suppression of proliferative response of human lymphocytes to mitogens.
R E Wolf
R E Wolf
Published April 1, 1979
Citation Information: J Clin Invest. 1979;63(4):677-683. https://doi.org/10.1172/JCI109350.
View: Text | PDF
Research Article

Thymosin-induced suppression of proliferative response of human lymphocytes to mitogens.

Abstract

The proliferative response of human peripheral blood lymphocytes to phytohemagglutinin, concanavalin A, and pokeweed mitogen were suppressed by thymosin. Greatest decreases were observed when cells were preincubated with thymosin for 18 h before a 3-d culture with mitogen in the presence of thymosin. However, significant suppression also occurred when lymphocytes were preincubated for 2 h and cultured with thymosin or preincubated for either 2 or 18 h and washed free of thymosin before culture. These effects were related to the concentration of thymosin and time of exposure to thymosin but not merely to a delay in the response to mitogen or to toxicity. The suppression of mitogen-induced proliferation by thymosin appeared to result from effects of thymosin on a suppressor cell because lymphocytes incubated with thymosin did not acquire increased responsiveness to mitogens as did cells incubated for 18 h in its absence and because mixing thymosin-pretreated lymphocytes with cells not preincubated with thymosin resulted in decreased responsiveness to photohemagglutinin.

Authors

R E Wolf

×

Guidelines

The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.

  • Comments appear on the Journal’s website and are linked from the original article’s web page.
  • Authors are notified by email if their comments are posted.
  • The Journal reserves the right to edit comments for length and clarity.
  • No appeals will be considered.
  • Comments are not indexed in PubMed.

Specific requirements

  • Maximum length, 400 words
  • Entered as plain text or HTML
  • Author’s name and email address, to be posted with the comment
  • Declaration of all potential conflicts of interest (even if these are not ultimately posted); see the Journal’s conflict-of-interest policy
  • Comments may not include figures
This field is required
This field is required
This field is required
This field is required
This field is required
This field is required
Rich Text Editor, eletter_body